Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Anti-PD-1 monoclonal antibodies, nivolumab and pembrolizumab, and anti-CTLA-4 antibody ipilimumab are being in clinic trials to treat melanoma. Here, we performed a meta-analysis to evaluate the efficacy and toxicity of them against advanced melanoma. METHODS: Eleven reports from 6 rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Chunyan, Tian, Jinhui, Liu, Huiling, Li, Fei, Niu, Hongxia, Zhu, Bingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500065/
https://www.ncbi.nlm.nih.gov/pubmed/28658143
http://dx.doi.org/10.1097/MD.0000000000007325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500065/
https://www.ncbi.nlm.nih.gov/pubmed/28658143
http://dx.doi.org/10.1097/MD.0000000000007325

Ejemplares similares